As reported in The Lancet Oncology by Paolo A. Ascierto, MD, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but statistically nonsignificant improvement with the addition of first-line atezolizumab to vemurafenib and cobimetinib in patients with BRAF V600–mutant advanced melanoma.
Clinical Trials
Metastatic Melanoma Treated Effectively with T Cell Therapy, Clinical Trial Shows
Results of the world’s first comparative phase III trial probing the efficacy of tumor infiltrating lymphocyte (TIL) therapy in solid tumors, support the use of the therapy in patients with advanced metastatic melanoma, an aggressive form of skin cancer. The results were published in The New England Journal of Medicine (NEJM) on December 8, 2022 “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.”
Personalised melanoma vaccines prolong survival in largest trial yet
People who received a personalised melanoma skin cancer vaccine on top of a standard treatment were less likely to die over the study period than those who had the standard treatment alone.
mRNA cancer vaccine combined with Keytruda promising in adjuvant treatment of melanoma
mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, with Keytruda met the primary endpoint of recurrence-free survival in a phase 2b trial for the adjuvant treatment of stage III/IV melanoma after surgical resection.